[go: up one dir, main page]

ZA958686B - Viral vectors and use in gene therapy - Google Patents

Viral vectors and use in gene therapy

Info

Publication number
ZA958686B
ZA958686B ZA958686A ZA958686A ZA958686B ZA 958686 B ZA958686 B ZA 958686B ZA 958686 A ZA958686 A ZA 958686A ZA 958686 A ZA958686 A ZA 958686A ZA 958686 B ZA958686 B ZA 958686B
Authority
ZA
South Africa
Prior art keywords
gene therapy
viral vectors
viral
vectors
therapy
Prior art date
Application number
ZA958686A
Other languages
English (en)
Inventor
Martin Lee
Michel Perricaudet
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA958686B publication Critical patent/ZA958686B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA958686A 1994-10-17 1995-10-13 Viral vectors and use in gene therapy ZA958686B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9412346A FR2725726B1 (fr) 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
ZA958686B true ZA958686B (en) 1996-05-22

Family

ID=9467911

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA958686A ZA958686B (en) 1994-10-17 1995-10-13 Viral vectors and use in gene therapy

Country Status (11)

Country Link
US (1) US6669942B2 (fr)
EP (1) EP0787198A1 (fr)
JP (1) JP3816952B2 (fr)
AU (1) AU712243B2 (fr)
CA (1) CA2201399A1 (fr)
FI (1) FI971613A7 (fr)
FR (1) FR2725726B1 (fr)
IL (1) IL115584A (fr)
NO (1) NO971590L (fr)
WO (1) WO1996012030A1 (fr)
ZA (1) ZA958686B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2161095A1 (fr) * 1993-04-20 1994-10-27 Solis Therapeutics, Inc. Methodes et produits pour le traitement d'individus contamines par des agents infectieux intracellulaires
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
DK0811073T3 (da) * 1995-02-24 2007-05-21 Univ Pennsylvania Avendelse af immunmodulatorer til fremstilling af medikamenter til inhibering af immunresponser mod co-administrerede rekombinanter
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
ES2333425T5 (es) * 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
DE69740033D1 (de) * 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
AU4255397A (en) * 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
EP1025242A1 (fr) 1997-10-30 2000-08-09 Cornell Research Foundation, Inc. Procede inhibant la reponse immunitaire a un vecteur recombine
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
AU4220600A (en) * 1999-04-09 2000-11-14 Schering-Plough Ltd Recombinant and mutant adenoviruses derived of bovine adenovirus type1
ATE485382T1 (de) * 1999-05-17 2010-11-15 Crucell Holland Bv Rekombinantes adenovirus des ad26-serotyps
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
CN1254719A (zh) * 1999-11-19 2000-05-31 钱其军 一种缺陷型腺病毒及其构建方法
EP1157999A1 (fr) * 2000-05-24 2001-11-28 Introgene B.V. Méthodes et moyens pour améliorer la transplantation de la peau en utilisant des vecteurs d'apport de genes munis d'un tropisme pour des fibroblastes primaires ainsi que d'autres utilisations de celles-ci
US20040033605A1 (en) * 2000-09-20 2004-02-19 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
EP1203819A3 (fr) 2000-10-06 2002-08-07 Transgene S.A. Vecteurs anti-inflammatoires
KR100432953B1 (ko) * 2001-09-01 2004-05-28 김주항 개선된 종양 살상 효과를 나타내는 재조합 아데노바이러스
ES2335657T3 (es) * 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
US8420611B2 (en) 2004-08-12 2013-04-16 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
EP2634252B1 (fr) 2005-02-11 2018-12-19 University of Southern California Procédé d'expression de protéines avec des ponts disulfures
US20060286074A1 (en) * 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
US9533036B2 (en) * 2005-11-07 2017-01-03 Microvax, Llc Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
WO2008095027A2 (fr) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Vecteur adenoviral comprenant une thymidine kinase de virus herpes simplex virus type 1 et un transgene pour augmenter l'expression du transgene
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US10837020B2 (en) * 2009-04-22 2020-11-17 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long RNA molecules
EP2421563B1 (fr) 2009-04-22 2017-04-12 Massachusetts Institute of Technology Suppression immunitaire innée permettant la distribution répétée de longues molécules d'arn
US20120237481A1 (en) * 2011-03-17 2012-09-20 Xiaoliu Zhang Incorporation of the B18R gene to enhance antitumor effect of virotherapy
US8445781B1 (en) 2011-11-15 2013-05-21 Nova D. Chasser Electrical receptacle cover having safety bracket for use with fragrance dispenser
KR102543774B1 (ko) 2016-09-20 2023-06-19 베링거잉겔하임베트메디카게엠베하 신규한 프로모터
JP6952112B2 (ja) 2016-09-20 2021-10-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 新規なｅｈｖ挿入部位ｏｒｆ７０
CN109715219B (zh) 2016-09-20 2024-03-01 勃林格殷格翰动物保健有限公司 犬腺病毒载体
KR102566066B1 (ko) 2016-09-20 2023-08-16 베링거잉겔하임베트메디카게엠베하 신규한 돼지 인플루엔자 백신
US11839655B2 (en) 2017-09-01 2023-12-12 Microvax, Llc Combination cancer therapy
WO2022070052A1 (fr) 2020-09-30 2022-04-07 Alma Bio Therapeutics Thérapie par acide nucléique pour la modulation différentielle de la microflore hôte

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2120503C (fr) * 1991-10-04 2006-04-04 Glenn Dranoff Regulation des reactions immunitaires systemiques a l'aide de cytokines et d'antigenes
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994004196A1 (fr) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Therapie de tumeurs
AU680459B2 (en) * 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.

Also Published As

Publication number Publication date
AU3658495A (en) 1996-05-06
US6669942B2 (en) 2003-12-30
NO971590D0 (no) 1997-04-07
US20020006395A1 (en) 2002-01-17
FI971613A0 (fi) 1997-04-16
EP0787198A1 (fr) 1997-08-06
IL115584A0 (en) 1996-01-19
WO1996012030A1 (fr) 1996-04-25
CA2201399A1 (fr) 1996-04-25
FR2725726A1 (fr) 1996-04-19
FR2725726B1 (fr) 1997-01-03
JP3816952B2 (ja) 2006-08-30
FI971613L (fi) 1997-04-16
AU712243B2 (en) 1999-11-04
NO971590L (no) 1997-04-07
FI971613A7 (fi) 1997-04-16
JPH10507079A (ja) 1998-07-14
IL115584A (en) 2005-11-20

Similar Documents

Publication Publication Date Title
ZA958686B (en) Viral vectors and use in gene therapy
ZA945012B (en) Viral vectors and their use in gene therapy
IL111681A0 (en) Recombinant viruses and their use in gene therapy
ZA951803B (en) Recombinant viruses their preparation and their therapeutic use
IL128882A0 (en) Viral vectors and their uses
ZA952563B (en) Recombinant viruses their preparation and their use in gene therapy
SG54275A1 (en) Dna coding for decarbamylase improved in thermostability and use thereof
ZA979096B (en) Viral and cancer treatment
PL322589A1 (en) Radiotracer-labelled peptides for use in diagnostics and therapy
GB9810423D0 (en) Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy
IL105914A0 (en) Methods and compositions for in vivo gene therapy
FI955154L (fi) Viruskombinantteja ja niiden käyttö geeniterapiassa
EP0752472A4 (fr) Nouveau gene tire de corynebacterium et son utilisation
IL111682A0 (en) Recombinant viruses and their use in gene therapy
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
AU1598599A (en) Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
ZA952242B (en) Recombinant viruses their preparation and their use in gene therapy
ZA983740B (en) Novel amidine derivatives and their use in therapy
FR2725213B1 (fr) Vecteurs viraux et utilisation en therapie genique
IL114688A0 (en) Vectors and transformed host cells
ZA952244B (en) Recombinant viruses their preparation and their use in gene therapy
GB9421223D0 (en) Tissue imaging in gene therapy
AP9500732A0 (en) Anti viral and anti cancer agents
ZA952286B (en) Recombinant viruses their preparation and their use in gene therapy
ZA952243B (en) Recombinant viruses their preparation and their use in gene therapy